ARTA
CTMX icon

A.R.T. Advisors’s CytomX Therapeutics CTMX Stock Holding History

A.R.T. Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-51,891
Closed -$383K – 1405
2019
Q3 		$383K Sell
51,891
-20,400
-28% -$201K 0.02% 958
2019
Q2 		$811K Buy
+72,291
New +$758K 0.05% 545
2018
Q3 		– Sell
-15,694
Closed -$358K – 1448
2018
Q2 		$358K Sell
15,694
-5,057
-24% -$129K 0.01% 1039
2018
Q1 		$590K Sell
20,751
-26,229
-56% -$749K 0.02% 879
2017
Q4 		$991K Buy
46,980
+32,968
+235% +$684K 0.04% 620
2017
Q3 		$254K Buy
+14,012
New +$219K 0.01% 1067
2017
Q2 		– Sell
-10,400
Closed -$179K – 1467
2017
Q1 		$179K Buy
+10,400
New +$137K 0.01% 1186

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

A.R.T. Advisors's CTMX Position: Q4 2019 in Review

A.R.T. Advisors sold out of CytomX Therapeutics (CTMX) in Q4 2019, closing a stake of 51,891 shares — an estimated $383K sold.

A.R.T. Advisors first reported a position in CTMX in Q1 2017 and held it in 7 quarters. The position peaked at $991K in Q4 2017. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2019.

  • A.R.T. Advisors reported no remaining CytomX Therapeutics position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 51,891 CytomX Therapeutics shares in Q4 2019, an estimated $383K.
  • A.R.T. Advisors first reported a position in CytomX Therapeutics in Q1 2017 and held it in 7 quarters.
  • A.R.T. Advisors's CytomX Therapeutics position peaked at $991K in Q4 2017.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.